Rosalee Zackula

Rosalee Zackula

Auto-generated profile, based on publicly available information

Rosalee Zackula

The University of Kansas School of Medicine-Wichita

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MMohammed Aseeri
Mohammed Aseeri
TSTodd Schroeder
Todd Schroeder
JKJoan Kramer
Joan Kramer
RZRosalee Zackula
Rosalee Zackula
Evidence for the association between Clostridium difficile (C. difficile) and the use of proton pump inhibitor (PPI) is unclear. This study investigated the relationship between Clostridium difficile-associated diarrhea (CDAD) and exposure to acid suppressive therapy in hospitalized adult patients while controlling for the most common predisposing risk factors. A retrospective case-control study was conducted at a local hospital of all hospitalized patients between October 1, 2005 and September 30, 2006 who developed CDAD during hospitalization. Subjects were determined to have CDAD if there was a positive C. difficile toxin and clinical correlation of diarrhea at the time of diagnosis. Subjects were pair-matched to controls on the following factors: admission date, antibiotic exposure, gender, age groups, patient location (medical or surgical unit), and room type at time of admission. Seven risk factors were assessed for association with onset of CDAD: exposure to PPIs or H(2)-blockers, renal failure, diabetes mellitus, immunosuppression, malignancy, and gastrointestinal disease. Ninety-four cases were successfully matched to controls. Cases were more likely than controls to receive acid suppressive therapy during hospitalization, 72 (76.6%) versus 40 (42.6%), respectively, P= 0.030. In a multivariate exact conditional logistic regression analysis, CDAD was associated with use of PPI (odds ratio [OR]= 3.6, 95% confidence interval [CI]= 1.7-8.3; P < 0.001), and with renal failure (OR = 5.7, CI = 1.3-39.1; P= 0.02). This study showed elevated risk of developing CDAD in hospitalized patients with acid suppressive therapy, especially when PPIs were used.


1 September 2014 in Hospital Pharmacy
Verified
Journal Article
Closed access
JKJoan S. Kramer
Joan S. Kramer
MSMichael R. Stewart
Michael R. Stewart
SFSarah M. Fogg
Sarah M. Fogg
BSBrandon C. Schminke
Brandon C. Schminke
RZRosalee E. Zackula
Rosalee E. Zackula
KGKreg W. Goertzen
Kreg W. Goertzen
Background/Objective: Medication reconciliation at transitions of care decreases medication errors, hospitalizations, and adverse drug events. We compared inpatient medication histories and reconciliation across disciplines and evaluated the nature of discrepancies.Methods: We conducted a prospective cohort study of patients admitted from the emergency department at our 760-bed hospital. Eligible patients had their medication histories conducted and reconciled in order by the admitting nurse (RN), certified pharmacy technician (CPhT), and pharmacist (RPh). Discharge medication reconciliation was not altered. Admission and discharge discrepancies were categorized by discipline, error type, and drug class and were assigned a criticality index score. A discrepancy rating system systematically measured discrepancies.Results: Of 175 consented patients, 153 were evaluated. Total admission and discharge discrepancies were 1,461 and 369, respectively. The average number of medications per participant at admission was 8.59 (1,314) with 9.41 (1,374) at discharge. Most discrepancies were committed by RNs: 53.2% (777) at admission and 56.1% (207) at discharge. The majority were omitted or incorrect. RNs had significantly higher admission discrepancy rates per medication (0.59) compared with CPhTs (0.36) and RPhs (0.16) ( P < .001). RPhs corrected significantly more discrepancies per participant than RNs (6.39 vs 0.48; P < .001); average criticality index reduction was 79.0%. Estimated prevented adverse drug events (pADEs) cost savings were $589,744.Conclusions: RPhs committed the fewest discrepancies compared with RNs and CPhTs, resulting in more accurate medication histories and reconciliation. RPh involvement also prevented the greatest number of medication errors, contributing to considerable pADE-related cost savings.

1 June 2010 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
MMMatthew Macaluso
Matthew Macaluso
RZRosey Zackula
Rosey Zackula
IDInna D'Empaire
Inna D'Empaire
BBBryan Baker
Bryan Baker
Kore Kai LiowKore Kai Liow
Kore Kai Liow
SPSheldon H. Preskorn
Sheldon H. Preskorn
The risk of dose-dependent seizures is a safety issue with bupropion hydrochloride. To evaluate the presence of specific electroencephalographic (EEG) waveforms, 210 adult subjects taking stable doses of bupropion hydrochloride were recruited to undergo 2 EEGs in a prospective, single-center cohort study. The occurrence of spike waves, sharp waves, and focal slowing was recorded and assessed with a continuation ratio logit model for polytomous responses. This model showed that there was a relationship between sex and the incidence of these waveforms, such that the odds of female subjects having sharp waves was increased by a factor of 2.53 (P = 0.05) when compared with male subjects and controlled for both age and dose. Similarly, female subjects were 2.45 (P = 0.09) times more likely than males to have focal slowing on EEG. Overall, 19.8% (39/197) of this representative population was found to have abnormal, asymptomatic EEG findings. The presence of these waveforms in individuals taking a medication known to lower the seizure threshold may be a risk factor for developing seizures.

1 November 2012 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
PDF file
RLRebecca L. Lamis
Rebecca L. Lamis
JKJoan S. Kramer
Joan S. Kramer
LHLaDonna S. Hale
LaDonna S. Hale
RZRosalee E. Zackula
Rosalee E. Zackula
GBGina M. Berg
Gina M. Berg
Purpose The association between fall risk and inpatient medications was evaluated. Methods A retrospective, case–control study was performed to compare the medication use of patients sustaining at least one fall during hospitalization (case group) with a control group of patients who did not fall. Data were collected from medical records and generated reports. A fall was defined by the hospital as an event in which the patient comes to rest on the floor from a lying, standing, or sitting position. Adult patients (≥18 years of age) admitted between January 1 and December 31, 2006, experiencing a fall at least 48 hours after hospital admission were included in the case group. Each case was matched with one control by age (within five years), sex, admission date (within 30 days), patient care unit, and length of stay. Medications administered within 48 hours before the fall for the case group or designated fall date and time for the control group were documented. Results Of the 414 documented fall events, 209 patients met the inclusion criteria. Of those patients, 96 matched control patients on all criteria. Significantly more case patients received a greater number of central nervous system (CNS) agents compared with matched control patients (p = 0.017). There was no statistically significant difference in the number of medications from all other drug classes or the total number of medications received by the groups. Conclusion In a sample of hospitalized patients, CNS agents were significantly associated with falls.

1 June 2017 in Journal of the American College of Radiology
Verified
Journal Article
Closed access
APAmy K. Patel
Amy K. Patel
JFJulia Fielding
Julia Fielding
KMKatarzyna J. Macura
Katarzyna J. Macura
KAKimberly E. Applegate
Kimberly E. Applegate
RZRosalee Zackula
Rosalee Zackula
EAElizabeth Kagan Arleo
Elizabeth Kagan Arleo